Intracoronary and peripheral blood levels of TNF-like Cytokine 1A (TL1A) in patients with acute coronary syndrome

Xinjing Chen, Yansong Guo, Li Lai, Shengli Zhang, Zhiliang Li, Xinjing Chen, Yansong Guo, Li Lai, Shengli Zhang, Zhiliang Li

Abstract

Background: TNF-like cytokine 1A (TL1A) is a subgroup of the tumor necrosis factor superfamily that exerts pleiotropic effects on cell proliferation, inflammation, activation, and differentiation of immune cells. The purpose of the current study is to investigate the clinical significance of TL1A expression in coronary and peripheral blood of patients with acute coronary syndrome (ACS) to determine if TL1A levels can serve as an accurate prognostic indicator.

Methods: A total of 141 patients undergoing coronary angiography were divided into 4 groups: Control (n = 35), Unstable Angina (UA) (n = 35), acute non-ST segment elevation myocardial infarction (NSTEMI) (n = 37), and acute ST segment elevation myocardial infarction (STEMI) (n = 34). The levels of TL1A, MPO, hs-CRP, and IL-10 were detected in coronary and peripheral blood using enzyme linked immunosorbent assay (ELISA), and the MACE incidence rates were compared during 26.3 months of follow-up.

Results: TL1A levels were not significantly different between the UA group and control group. In the UA group, TL1A levels were not significantly different between coronary blood and peripheral blood. However, TL1A levels were higher in the STEMI and NSTEMI groups than in the control group (P < .05). Moreover, TL1A levels in the coronary blood of the STEMI and NSTEMI groups were higher than in the peripheral blood (P < .05). The expression of TL1A in the coronary blood was the highest in the STEMI group. In addition, TL1A level in the coronary blood was highly correlated with levels in the peripheral blood (correlation coefficient: 0.899, P < .001). The hs-CRP and MPO levels in the coronary and peripheral blood of all the UA, NSTEMI, and STEMI groups were higher than the control group. Plasma IL-10 levels in all the UA, NSTEMI and STEMI groups were lower than those in the control group. Plasma TL1A level was positively correlated with the cTnI level, degree of coronary thrombus burden, occurrence of slow coronary flow / no coronary reflow and MACE, but negatively correlated with the IL-10 level or non-correlated with the Syntax score.

Conclusion: Plasma TL1A concentration levels can be used as a predictor of inflammatory response and prognosis in patients with ACS.

Trial registration: ClinicalTrials.gov, number: NCT02430025; Unique Protocol ID: FJPH20150101; Brief Title: Fujian Province Cardiovascular Diseases Study (FJCVD).

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Cichoń N, Lach D, Dziedzic A, et al. The inflammatory processes in atherogenesis. Pol Merkur Lekarski 2017;42:125–8.
    1. Ray M, Autieri MV. Regulation of pro- and anti-atherogenic cytokines. Cytokine 2019;122:154175.
    1. O’Neal WT, Soliman EZ, Howard G, et al. Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The Reasons for Geographic And Racial Differences in Stroke study. Atherosclerosis 2015;243:192–7.
    1. Geng YJ. Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Ann N Y Acad Sci 2003;1010:687–97.
    1. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002;16:479–92.
    1. Wakiyama H, Cowan DB, Toyoda Y, et al. Selective opening of mitochondrial ATP-sensitive potassium channels during surgically induced myocardial ischemia decreases necrosis and apoptosis. Eur J Cardiothorac Surg 2002;21:424–33.
    1. Elsasser A, Suzuki K, Lorenz-Meyer S, et al. The role of apoptosis in myocardial ischemia: a critical appraisal. Basic Res Cardiol 2001;96:219–26.
    1. Kim WJ, Kang YJ, Suk K, et al. Comparative analysis of the expression patterns of various TNFSF/TNFRSF in atherosclerotic plaques. Immunol Invest 2008;37:359–73.
    1. Kang YJ, Kim WJ, Bae HU, et al. Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 2005;29:229–35.
    1. Kim WJ, Bae EM, Kang YJ, et al. Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology 2006;119:421–9.
    1. Section of Interventional Cardiology of Chinese Society of Cardiology of Chinese Medical Association, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, and Editorial Board of Chinese Journal of Cardiology. Chinese guideline for percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 2016;44:382–400.
    1. Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol 2018;81:241–330.
    1. Kim SH, Lee WH, Kwon BS, et al. Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. Jpn Circ J 2001;65:136–8.
    1. Li H, Song J, Niu G, et al. TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice. Pathol Res Pract 2018;214:217–27.
    1. Ma Z, Wang B, Wang M, et al. TL1A increased IL-6 production on fibroblast-like synoviocytes by preferentially activating TNF receptor 2 in rheumatoid arthritis. Cytokine 2016;83:92–8.
    1. Wang NG, Wang F, Tan BY, et al. Genetic analysis of TNFST15 variants in ankylosing spondylitis. Int J Clin Exp Pathol 2015;8:15210–5.
    1. Kim S, Kotoula V, Hytiroglou P, et al. Significance of increased expression of decoy receptor 3 in chronic liver disease. Dig Liver Dis 2009;41:591–8.
    1. Richard AC, Ferdinand JR, Meylan F, et al. The TNF-family cytokine TL1A: From lymphocyte costimulator to disease co-conspirator. J Leukoc Biol 2015;98:333–45.
    1. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496–508.
    1. Avci E, Yildirim T, Aydin G, et al. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci 2018;22:4987–94.
    1. Li H, Fu DG, Liu FY, et al. Evaluation of related factors, prediction and treatment drugs of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction after direct PCI. Exp Ther Med 2018;15:3940–6.
    1. Kuznetsov VA, Bessonov IS, Zyrianov IP, et al. Comparison of direct stenting versus stending after pre-dilation in st-elevation myocardial infarction. Kardiologiia 2017;57:5–10.
    1. Hashemi-Jazi M, Hosseini SM, Gholamrezaei A. Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 2017;13:221–9.
    1. Liang T, Liu M, Wu C, et al. Risk factors for no-reflow phenomenon after percutaneous coronary intervention in patients with acute coronary syndrome. Rev Invest Clin 2017;69:139–45.
    1. Hodzic E. Potential anti-inflammatory treatment of ischemic heart disease. Med Arch 2018;72:94–8.
    1. Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun 2018;70:61–75.
    1. Aratani Y. Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys 2018;640:47–52.
    1. Wang MJ, Xu YG, Ding XQ, et al. Secretory imbalance between pro-inflammatory and anti-inflammatory cytokines in the patients with immune. Thrombocytopenia 2018;26:522–7.
    1. Stamatelopoulos K, Georgiou S, Kanakakis I, et al. Circulating levels of tnf-like cytokine 1a correlate with reflected waves and atherosclerosis extent and may predict cardiac death in patients with stable coronary artery disease. Cytokine 2015;72:102–4.
    1. van der Wall EE. ESC Congress 2008 in Munich: Hot news from Hot lines!. Neth Heart J 2008;16:367–8.
    1. Serruys PW, Moriee MC, Kappetein AP. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961–6.
    1. Chang TY, Hsu CY, Huang PH, et al. Usefulness of circulating decoy receptor 3 in predicting coronary artery disease severity and future major adverse cardiovascular events in patients with multivessel coronary artery disease. Am J Cardiol 2015;116:1028–33.
    1. Sorrentino S, Iaconetti C, De Rosa S, et al. Hindlimb ischemia impairs endothelial recovery and increases neointimal proliferation in the carotid artery. Sci Rep 2018;8:761.
    1. Liu J, Sun F, Wang Y, et al. Suppression of microrna-16 protects against acute myocardial infarction by reversing beta2-adrenergic receptor down-regulation in rats. Oncotarget 2017;8:20122–32.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir